{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:59:08Z","timestamp":1788994748695,"version":"build-2803163510"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,10]]},"DOI":"10.7759\/cureus.60051","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T18:10:32Z","timestamp":1715364632000},"source":"Crossref","is-referenced-by-count":3,"title":["Paradoxical Eczematous Reaction in a Patient With IL-17 Inhibitor-Treated Psoriasis Vulgaris"],"prefix":"10.7759","author":[{"given":"Brett","family":"Brazen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Colon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Nousari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44050127","article-title":"The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases","volume":"44","author":"\u021aiburc\u0103 L","year":"2022","unstructured":"\u021aiburc\u0103 L, Bembea M, Zaha DC, Jurca AD, Vesa CM, Ra\u021biu IA, Jurca CM. The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases. Curr Issues Mol Biol. 2022, 44:1851-66. 10.3390\/cimb44050127","journal-title":"Curr Issues Mol Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/20406223231163110","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials","volume":"14","author":"Wang Y","year":"2023","unstructured":"Wang Y, Li S, Bai J, et al.. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials. Ther Adv Chronic Dis. 2023, 14:20406223231163110. 10.1177\/20406223231163110","journal-title":"Ther Adv Chronic Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7388","article-title":"A case series of patients with eczematous eruptions following IL-17 inhibitor treatment for psoriasis vulgaris","volume":"22","author":"Yousif J","year":"2023","unstructured":"Yousif J, Al-Dehneem R, Kaskas N, Gottlieb AB. A case series of patients with eczematous eruptions following IL-17 inhibitor treatment for psoriasis vulgaris. J Drugs Dermatol. 2023, 22:1225-7. 10.36849\/JDD.7388","journal-title":"J Drugs Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.993057","article-title":"Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review","volume":"14","author":"Wang J","year":"2023","unstructured":"Wang J, Wang C, Liu L, et al.. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. Front Immunol. 2023, 14:993057. 10.3389\/fimmu.2023.993057","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032844","article-title":"Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: a case report","volume":"102","author":"Xiao Y","year":"2023","unstructured":"Xiao Y, Peng S, Li X, Mao T, Fang M, Hu Y, Ye W. Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: a case report. Medicine (Baltimore). 2023, 102:e32844. 10.1097\/MD.0000000000032844","journal-title":"Medicine (Baltimore)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000513467","article-title":"Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis","volume":"13","author":"Mendes Roncada EV","year":"2021","unstructured":"Mendes Roncada EV, Brambilla VR, Freitas Filitto B, Genta MP, Morgado de Abreu MA. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis. Case Rep Dermatol. 2021, 13:336-9. 10.1159\/000513467","journal-title":"Case Rep Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky E","year":"2017","unstructured":"Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. Curr Opin Immunol. 2017, 48:68-73. 10.1016\/j.coi.2017.08.008","journal-title":"Curr Opin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/247628-paradoxical-eczematous-reaction-in-a-patient-with-il-17-inhibitor-treated-psoriasis-vulgaris","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T18:10:34Z","timestamp":1715364634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/247628-paradoxical-eczematous-reaction-in-a-patient-with-il-17-inhibitor-treated-psoriasis-vulgaris"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.60051","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}